Compare Recursion Pharmaceuticals Inc (RXRX) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs SpaceX — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while SpaceX trades at $147.13 (market cap $2.02T). The key difference: SpaceX is far larger — about 1086× Recursion Pharmaceuticals Inc's market cap, and SpaceX is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SPCX | |
|---|---|---|
Market Cap | $1.86B | $2.02T |
Sector | Health | Technology |
52-Week High | $6.79 | $202.09 |
52-Week Low | $2.84 | $108.27 |
Enterprise Value | $1.38B | $1.96T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
SPCX trades at $153.47, up 3.73% today, with strong analyst support (90% buy ratings) and a $227.22 consensus price target suggesting 48% upside. Despite negative profitability metrics, the company shows robust revenue growth and significant cash flow generation. Technical indicators show a bullish trend with key support at $147 and resistance at $157. Recent news highlights insider share unlocks creating temporary selling pressure but strong institutional interest.
The outlook remains positive given SpaceX's innovation pipeline and market leadership, though investors face risks from high valuation multiples, ongoing losses, and competitive pressures. The stock's premium valuation requires continued execution on growth targets to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
